MindRhythm is medical technology company focused on preventing neurological injury in stroke.

The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.

Experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021.

The Lancet reports that patients receiving Vivistim® Paired VNS™ System therapy showed 2-3 times the improvement in upper extremity motor impairment and function compared to controls that received intense rehabilitation alone.

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac’s Fast Track Designation.

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.